2026 ICD-10-CM Diagnosis Code E72.04Cystinosis

ICD-10-CM CodesE00–E89E70-E88E72

ICD-10-CM E72.04
CMSSource: CMS FY 2026 ICD-10-CM dataset · Effective Oct 1, 2025 – Sep 30, 2026

E72.04 is a billable ICD-10-CM diagnosis code for cystinosis. It is valid on HIPAA claims for fiscal year 2026 (October 1, 2025 through September 30, 2026). Coders also document this condition as benign adult cystinosis. In AHRQ's Clinical Classifications Software (CCSR), this diagnosis falls under Other specified and unspecified nutritional and metabolic disorders.

Code Identity

ICD-10-CM Code
E72.04
Billable Status
Yes — Valid for Submission
Code Describes
Cystinosis
Short Description
Cystinosis
Same as the full description in the CMS dataset.
Parent Code
Disorders of amino-acid transport

Code Classification

ChapterE00–E89Endocrine, nutritional and metabolic diseases
SectionE70-E88Metabolic disorders
CategoryE72Other disorders of amino-acid metabolism
This CodeE72.04Cystinosis

Approximate SynonymsGuidance

Alternate terms and clinical phrases that map to this code.

  • Benign adult cystinosis
  • Congenital Fanconi syndrome
  • Cystinosis
  • Hypothyroidism due to cystinosis
  • Hypothyroidism due to infiltrative disease
  • Infantile nephropathic cystinosis
  • Juvenile nephropathic cystinosis
  • Renal tubulo-interstitial disorder due to cystinosis

Tabular List NotesGuidance

Coding notes and annotation back-references applicable to this code.

Inclusion Terms

  • Fanconi (-de Toni) (-Debré) syndrome with cystinosis

Type 1 Excludes

  • Fanconi -de Toni -Debré syndrome without cystinosis E72.09

Index to Diseases and InjuriesGuidance

External Cause of Injuries IndexGuidance

References for this code in the External Cause of Injuries Index.

    • Abderhalden-Kaufmann-Lignac syndrome(cystinosis)
    • Cystinosis(malignant)
    • De Toni-Fanconi(-Debré) syndrome
      • with cystinosis
    • Disease, diseased
      • Lignac's (cystinosis)
    • Disorder(of)
      • amino-acid
        • cystinosis
    • Disorder(of)
      • tubulo-interstitial (in)
        • cystinosis
    • Fanconi(-de Toni)(-Debré) syndrome
      • with cystinosis
    • Lignac(-de Toni) (-Fanconi) (-Debré) disease or syndrome
      • with cystinosis
    • Pyelonephritis
      • in (due to)
        • cystinosis
    • Syndrome
      • de Toni-Fanconi (-Debré)
        • with cystinosis
    • Syndrome
      • Fanconi (-de Toni) (-Debré)
        • with cystinosis
    • Syndrome
      • Lignac (de Toni) (-Fanconi) (-Debré)
        • with cystinosis
    • Syndrome
      • Toni-Fanconi
        • with cystinosis
    • Toni-Fanconi syndrome(cystinosis)
      • with cystinosis

Clinical ClassificationClinical

AHRQ’s CCSR groups this code into broader clinical categories.

CCSR END016
Other specified and unspecified nutritional and metabolic disorders
Default principal diagnosis: inpatient Yes · outpatient Yes

Clinical InformationClinical

  • Cystinosis

    a metabolic disease characterized by the defective transport of cystine across the lysosomal membrane due to mutation of a membrane protein cystinosin. this results in cystine accumulation and crystallization in the cells causing widespread tissue damage. in the kidney, nephropathic cystinosis is a common cause of renal fanconi syndrome.
  • CTNS wt Allele|CTNS-LSB|Cystinosin, Lysosomal Cystine Transporter wt Allele|Cystinosis Nephropathic Gene|Cystinosis, Nephropathic Gene|PQLC4|SLC66A4

    human ctns wild-type allele is located in the vicinity of 17p13.2 and is approximately 27 kb in length. this allele, which encodes cystinosin protein, plays a role in cystine/proton symport. mutation of the gene is associated with multiple forms nephropathic cystinosis including the atypical, the ocular and the late-onset juvenile or adolescent forms.
  • Cystinosis

    an autosomal recessive hereditary disorder characterized by defective transportation of cystine across the lysosomal membranes and systemic deposition of cystine crystals in the body. it is associated with slight increase of the plasma cystine, cystinuria, aminoaciduria, glycosuria, polyuria, hypophosphatemia, rickets, and renal tubular dysfunction.
  • Nephropathic Cystinosis

    an autosomal recessive condition caused by mutation(s) in the ctns gene, encoding cystinosin. it is a sub-type of cystinosis, in which accumulation of cystine in the kidney results in renal dysfunction.

Patient EducationClinical

Kidney Diseases

You have two kidneys, each about the size of your fist. They are near the middle of your back, just below the rib cage. Inside each kidney there are about a million tiny structures called nephrons. They filter your blood. They remove wastes and extra water, which become urine. The urine flows through tubes called ureters.

Read the full article at MedlinePlus

Courtesy of MedlinePlus, a service of the U.S. National Library of Medicine.

Convert E72.04 to ICD-9-CMHistory

The closest ICD-9-CM equivalents under the General Equivalence Mappings.

ICD-9-CM
270.0 Amino-acid transport dis
Approximate The match is approximate rather than exact.

Code HistoryHistory

FY 2016AddedAdded to the ICD-10-CM code setEffective October 1, 2015, the first year of ICD-10-CM.
FY 2017–2025No changes
FY 2026CurrentCurrent code set, no changesEffective October 1, 2025 through September 30, 2026.

Questions About E72.04Overview

Is E72.04 (Disorders of amino-acid transport) a billable code?

Yes. This is a billable ICD-10-CM code, specific enough to report cystinosis on HIPAA-covered claims from October 1, 2025 through September 30, 2026.

What is the ICD-9 equivalent of E72.04?

Under the General Equivalence Mappings, cystinosis converts to ICD-9-CM 270.0 (amino-acid transport dis). The mapping is approximate, so confirm the match fits the documentation.

Footnotes

[1] Chronic - a chronic condition code indicates a condition lasting 12 months or longer and its effect on the patient based on one or both of the following criteria:

  • The condition results in the need for ongoing intervention with medical products,treatment, services, and special equipment
  • The condition places limitations on self-care, independent living, and social interactions.